Efficacy and safety of new drugs for induction, autologous stem cell transplantation, consolidation and maintenance therapy in patients with newly diagnosed elderly symptomatic multiple myeloma: phase 2 study FBMTG EMM17
Not Applicable
Recruiting
- Conditions
- Multiple myeloma
- Registration Number
- JPRN-UMIN000028421
- Lead Sponsor
- FBMTG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 49
Inclusion Criteria
Not provided
Exclusion Criteria
1) Non-secretory MM and plasma cell leukemia. 2) Patients HIV-positive 3) Severe hepatic dysfunction, severe renal failure, severe cardiac dysfunction, severe pulmonary dysfunction, uncontrolled diabetes, uncontrolled hypertension, and uncontrolled infection. 4) Patients with a history of active malignancy during the past 5 years. 5) Patients with psychiatric disorders such as schizophrenia etc. 6) Pregnant women, pre-menopausal women, and lactating women. 7) History of hypersensitivity to mannitol or boron. 8) Patient was suspected pneumonia(Interstitial pneumonia). Consult a respiratory specialist if necessary 9) Those who are considered as inappropriate to register by attending physicians.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method